rhIL-7-hyFc in Increasing Lymphocyte Counts in Patients with Newly Diagnosed Gliomas

Inclusion Criteria

• World Health Organization (WHO) grade III, grade IV, and high risk grade II gliomas that require radiation therapy (RT) and temozolomide (TMZ) treatment
• Phase 2 Expansion Cohort ONLY: Must be IDH1 wildtype, as defined by negative immunohistochemistry using an R132H-specific antibody, and MGMT promoter unmethylated glioblastoma multiforme (WHO grade IV)
• Post-operative treatment must have included radiation and TMZ. Prior Gliadel wafers are allowed. Glucocorticoid therapy is allowed. Tumor treating field (TTF) device is allowed
• Absolute neutrophil count >= 1,000/mcL
• Platelets >= 75,000/mcL
• Hemoglobin >= 8 g/dL
• Total bilirubin =< 3.0 x institutional upper limit of normal
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional upper limit of normal
• Absolute blood lymphocyte count (ALC) >= 600/mcL (required for phase I and randomized phase II only)
• Karnofsky performance status (KPS) >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
• Able to provide written informed consent (or consent from a legally authorized representative)
• Women of childbearing potential must have a negative serum pregnancy test prior to study entry (within 14 days). Patients must be willing to be on adequate contraception during treatment
• >= 18 years of age

Exclusion Criteria

• Receiving any other investigational agents which may affect patient’s lymphocyte counts
• Pregnant women are excluded from this study because rhIL-7-hyFc has not been evaluated regarding its potential for teratogenic or abortifacients effects. There is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drug, breastfeeding should be discontinued if the mother is treated with rhIL-7-hyFc
• Has an active viral infection requiring systemic treatment at screening
• Has active autoimmune disease or syndrome (i.e. moderate or severe rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn’s disease, autoimmune hepatitis, granulomatosis with polyangiitis, etc.,) that requires systemic treatment at the time of screening. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Subjects are permitted to enroll if they have vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
• Receipt of live attenuated vaccine within 30 days before the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), Zoster, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed
• Has clinically significant cardiac enzymes ([Tnl or TnT] or CK-MB)
• Patients with a clinically significant electrocardiogram (EKG) on screening triggering a echocardiogram which is also clinically significant